No Data
Analysts Are Bullish on These Healthcare Stocks: Neumora Therapeutics, Inc. (NMRA), IDEAYA Biosciences (IDYA)
Buy Rating Affirmed for IDEAYA Biosciences Amid Promising Clinical Updates and Pipeline Catalysts
Unveiling 5 Analyst Insights On IDEAYA Biosciences
In the preceding three months, 5 analysts have released ratings for IDEAYA Biosciences (NASDAQ:IDYA), presenting a wide array of perspectives from bullish to bearish.The following table encapsulates t
IDEAYA Biosciences Price Target Maintained With a $52.00/Share by Wedbush
IDEAYA Biosciences Price Target Maintained With a $52.00/Share by Wedbush
Wedbush Reiterates Outperform on IDEAYA Biosciences, Maintains $52 Price Target
Wedbush analyst Robert Driscoll reiterates IDEAYA Biosciences with a Outperform and maintains $52 price target.
IDEAYA Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 23.77% Wedbush → $52 Reiterates Outperform → Outperform 03/21/2024 42.81% Citigroup $40 → $60 M